Endocrine Abstracts

Objective: The aim of our study was to evaluate the possibility of maintaining the metabolic effects of liraglutide 3.0 mg treatment after it’s cessation.Methods: The study included 8 patients with type 2 diabetes (T2D) and obesity who received liraglutide 3.0 mg daily for 9 months. All of them successfully reduced body weight, insulin resistance level (IR), volume of visceral adipose tissue, HbA1c level. After discontinuation of liraglutide in 2019...

Aim of the study: To analyze the dynamics and levels of incretins and neuropeptides secretion in patients with CD and acromegaly and therefore to specify the pathogenesis of carbohydrate metabolism disturbances.Methods: Forty-two patients with Cushing disease and acromegaly were included into the study. All patients were newly diagnosed with Cushing disease and acromegaly. Oral glucose tolerance test (OGTT), during which glucose, glucagon, glucagon like ...

Introduction: LADA exhibits characteristics of both type 1 diabetes mellitus (DM) and type 2 DM. Patients with LADA usually have some components of metabolic syndrome. GLP-1 agonists have been widely used in type 2 DM. GLP-1 agonist therapies have shown some promising glucose lowering effect in T1DM. Almost no information is available on glucagon and incretin secretion in patients with LADA as well as effects on glucose and C-peptide levels.Case report: ...

Introduction: Pituitary apoplexy is the rare case of panhypopituitarism. We are presenting a clinical case of pituitary apoplexy in a previously healthy 37-year-old woman.Case report: A 37-year-old woman developed amenorrhea in August 2011. She did not visit a doctor in that time. In December 2011 she suddenly felt severe headache, symptoms of polyuria and polydipsia and temperature of 39 °C. Laboratory results revealed an increased erythrocyte sedi...

Introduction: Resistance to thyroid hormone (RTH) is a rare disorder characterized by reduced tissues’s responsiveness to thyroid hormones (TH). Usually patients with RTH have not clinical signs except goiter. We describe a 70-years old woman with RTH and autoimmune thyroiditis simultaneously.Case report: Woman 70-years old was hospitalized in our department on August 2011 with suspicious of Thyrotropinoma because of high levels of TSH and fT4<...

Goal: Study thyroid function in patients with acromegaly. Materials and method: 88 patients with acromegaly, age 54.6±13.2 years, mediana diagnosis acromegaly 4 years, IGF1 528 (265; 701.3 ng/ml, HG 10.4 (3.7; 30.1) μE/ml, only 12 patients had a remission of disease. All patients were taken TSH, fT4, TPO antibodies, revealed anamnesis of thyroid diseases.Results: 19 from 88 patients (21.6%) had hypothyreosis and 2 (2.3%) had subclini...

Aim: To estimate efficiency of 200 mkg/day iodine for prevention of development of hypothyroxinemia in pregnant women with non toxic goiter and without it, who were living in region with mild iodine – deficiency.Subjects and methods: Study group consists of 32 pregnant women: 16 – with non toxic goiter (8 from them took 200 mkg of iodine), 16 - without thyroid disease (8 from them took 200 mkg of iodine).Results: Pregnant...

Background and aims: Hypoglycemia can be a risk factor for adverse cardiovascular and cerebrovascular events. However, changes in platelets and coagulation hemostasis during hypoglycemia have not been extensively studied. The aim of this study was to assess the impact of insulin-induced hypoglycemia on the platelet activity, endothelial dysfunction and the physiological anticoagulant level in patients with DM1.Research design and methods: We studied seve...

Introduction: Obesity and diabetes mellitus type 2 (T2DM) are considered as one of the major risk factor for coronary heart disease (CHD) development, but the mechanisms beyond this relationship still need to be clarified. miRNAs are supposed to be involved in regulatory mechanisms in this relationship.Aim: To determine miRNAs expression in patients with obesity and T2DM.Methods: MiRNAs were detected in peripheral blood of 43 patie...

Introduction: Obesity and type 2 diabetes mellitus (T2DM) are associated with cardiovascular diseases (CVD). Fibrotic changes in obesity include several molecular processes, including activation of Transforming growth factor β (TGF-β). Recent data indicate the involvement of Fibroblast growth factor 21 (FGF-21) as an important metabolic regulator, and even biomarker of metabolic changes in obesity and T2DM.Aim: To determine TGF-β and FGF-2...